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Hypertension is a very common comorbidity and major risk factor for cardiovascular compli-
cations, especially in people with Type 2 Diabetes (T2D). Nevertheless, studies in the past
have shown that blood pressure is often insufficiently controlled in medical practice. For the
DIAB-CARE study, we used longitudinal data based on the German DIAB-CORE Consor-
tium to assess whether health care regarding hypertension has improved during the last
decade in our participants.
Methods
Data of the three regional population-based studies CARLA (baseline 2002-2006 and fol-
low-up 2007-2010), KORA (baseline 1999-2001 and follow-up 2006-2008) and SHIP (base-
line 1997-2001 and follow-up 2002-2006) were pooled. Stratified by T2D status we
analysed changes in frequencies, degrees of awareness, treatment and control. Linear
mixed models were conducted to assess the influence of sex, age, study, and T2D status
on changes of systolic blood pressure between the baseline and follow-up examinations
PLOSONE | DOI:10.1371/journal.pone.0133493 July 29, 2015 1 / 16
OPEN ACCESS
Citation: Rückert I-M, Baumert J, Schunk M, Holle R,
Schipf S, Völzke H, et al. (2015) Blood Pressure
Control Has Improved in People with and without
Type 2 Diabetes but Remains Suboptimal: A
Longitudinal Study Based on the German DIAB-
CORE Consortium. PLoS ONE 10(7): e0133493.
doi:10.1371/journal.pone.0133493
Editor: Rudolf Kirchmair, Medical University
Innsbruck, AUSTRIA
Received: November 19, 2014
Accepted: June 28, 2015
Published: July 29, 2015
Copyright: © 2015 Rückert et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: The authors confirm
that, for approved reasons, access restrictions apply
to the data underlying the findings and thus they
cannot be made freely available in the manuscript,
the supplemental files, or a public repository. The
data are subject to national data protection laws and
restrictions were imposed by the Ethics Committees
to ensure data privacy of the study participants.
However, they can be applied for through an
individual project agreement with KORA, CARLA and
SHIP. Applications for access to the data sets can be
(mean observation time 5.7 years). We included 4,683 participants aged 45 to 74 years with
complete data and accounted for 1,256 participants who were lost to follow-up by inverse
probability weighting.
Results
Mean systolic blood pressure decreased in all groups from baseline to follow-up (e.g. – 8.5
mmHg in those with incident T2D). Pulse pressure (PP) was markedly higher in persons
with T2D than in persons without T2D (64.14 mmHg in prevalent T2D compared to 52.87
mmHg in non-T2D at baseline) and did not change much between the two examinations.
Awareness, treatment and control increased considerably in all subgroups however, the
percentage of those with insufficiently controlled hypertension remained high (at about 50%
of those with hypertension) especially in prevalent T2D. Particularly elderly people with T2D
often had both, high blood pressure140/90 mmHg and a PP of60 mmHg. Blood pres-
sure in men had improved more than in women at follow-up, however, men still had higher
mean SBP than women at follow-up.
Conclusion
Blood pressure management has developed positively during past years in Germany.
While hypertension prevalence, awareness and treatment were substantially higher in
participants with T2D than in those without T2D at follow-up, hypertension control was




The UK Hypertension in Diabetes Study, a sub-study of the UK Prospective Diabetes Study,
was the first to reveal that hypertension is very common in people with T2D and that treatment
and control are safe and can have great beneficial effects in terms of a reduction of cardiovascu-
lar morbidity and mortality [1]. These findings date back to 1998 and thus are relatively novel.
Since then hypertension and T2D have been studied more intensively, and numerous guide-
lines by international expert committees have been devised in order to instruct and support
physicians in the treatment of patients with hypertension and T2D (e.g. [2, 3]).
However, it has also turned out, that blood pressure control remains a complicated and
problematic issue in Germany and throughout the world [4, 5]. People with hypertension are
often unaware of their disease, they appear to underestimate the clinical significance of high
blood pressure, and/or do not achieve their treatment goals because of various reasons (e.g. [6,
7]). Moreover, there has been a controversial discussion about which blood pressure parameter
actually is most important for risk prediction and should be focussed on in clinical practise.
Systolic blood pressure (SBP) rises with advancing age, while diastolic blood pressure (DBP)
tends to drop, which is a sign of an increasing stiffness of the large arteries [8]. Pulse pressure
(PP) unites both components and is defined as the difference of SBP and DBP. A deviation of
more than around 60 mmHg is considered as a risk factor for cardiovascular events and mor-
tality (e.g. [9, 10]) and is found more often in older people due to the shifts of SBP and DBP in
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association with age. Most analyses, however, point to the importance of SBP [11, 12]. The
guidelines and cut-points to define hypertension have also changed over time with additional
medical insights. So far, it is not clear, whether people at higher risk of cardiovascular events
really benefit from blood pressure values of<130/80 mmHg (as recommended by the WHO/
ISH in 2003 [13]) compared to the more conservative categorization of<140/90 mmHg. The
American Diabetes Association, for example, currently recommends a target of<140/80
mmHg for people with diabetes [2]. Yet, the risk for cardiovascular disease appears to rise con-
tinuously starting with “normal” and “high normal” readings [14, 15].
During the study period of the DIAB-CORE studies, national German guidelines on the
therapy of diabetes recommended an ideal blood pressure of<130/85 mmHg, values between
130/85 mmHg and 140/90 mmHg were considered as elevated and values>140/90 mmHg as
high risk conditions. In due consideration of the patient’s age, general health and further
comorbidities, values>130/85 mmHg could be acceptable in individual cases [16]. The newest
update from 2014 states<140/80 mmHg as therapeutic aim [17]. Since specific differing values
for elderly people were not mentioned in these guidelines, we used a conservative cut-point of
140/90 mmHg for all participants in the current analyses.
By all means, hypertension and T2D are common conditions in developed societies and the
prevalences have been increasing noticeably in developing countries [18]. Cardiovascular risk
factors used to be absent in traditional folks e.g. the Solomon Islands societies [19] and are very
variable in different ethnicities and with changing lifestyles [20, 21], which implies that
improved health behaviour and treatment should be effective in bringing the hypertension epi-
demic under control (e.g. by improving dietary factors [22]). The current analysis was intended
to contribute information on the development of hypertension frequency, awareness, treat-
ment and control in people with and without T2D in Germany.
Objectives
Using baseline data of the German DIAB-CORE Consortium, we described insufficient blood
pressure control and medication in persons with T2D in two previous publications [23, 24].
The successor study DIAB-CARE included follow-up data of three DIAB-CORE studies and
aimed at the examination of changes in blood pressure control in participants with and without
T2D during approximately ten years (study period 1997–2010). We looked at different blood
pressure parameters and applied descriptive methods and multivariable adjusted regression
models.
Materials and Methods
Study design and setting
The current analysis included data from three population-based studies in Germany that are
part of the DIAB-CORE Consortium (from north to south): the Study of Health in Pomerania
(SHIP, Greifswald), the Cardiovascular Disease, Living and Ageing (CARLA, Halle (Saale))
Study, and the Cooperative Health Research in the Region of Augsburg (KORA, Augsburg)
Study, see Table 1. Baseline examinations of the studies were conducted between 1997 and
2006, follow-up examinations between 2002 and 2010. Similar instruments, questionnaires and
medical measurements were used to assess participants’ characteristics. Detailed descriptions
of study designs, samples and procedures are available elsewhere [25–27]. The investigations
were carried out in accordance with the Declaration of Helsinki, including written informed
consent of all participants. All study methods were approved by the Ethics Committee of the
Medical Faculty of the Martin-Luther-University Halle-Wittenberg and by the State Data Pri-
vacy Commissioner of Saxony-Anhalt (CARLA), the Ethics Committee of the Bavarian
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Medical Association (KORA) and the Medical Ethics Committee of the University of Greifs-
wald (SHIP). Primary study data of interest were pooled and frequencies compared.
Variables
Age. Participants were classified in three age groups ranging from 45 to 54, 55 to 64 and
65 to 74 years at baseline.
Type 2 diabetes. T2D was defined based on self-report or self-reported intake of oral anti-
diabetic agents, insulin or a combination of both. Some studies lacked information on diabetes
type. Thus, in order to exclude participants who probably had type 1 diabetes, self-reported age
at diagnosis of diabetes was used, and only those patients with an age at diagnosis of> 30 years
were included in the T2D group. T2D status with respect to baseline and follow-up examina-
tions was defined in three groups: i) no T2D at baseline, no T2D at follow-up, ii) no T2D at
baseline, T2D at follow-up (incident), iii) T2D at baseline, T2D at follow-up (prevalent).
Hypertension. In all three studies blood pressure measurements were carried out accord-
ing to the same study protocol by trained and certified personnel with an automated oscillo-
metric device (HEM-705CP, Omron Corporation, Tokyo, Japan). The measurements were
taken after a rest period of at least five minutes in a sitting position and repeated three times at
an interval of three minutes.
Hypertension was defined using the mean of the second and third blood pressure readings
with SBP140 mmHg and/or DBP90 mmHg, or intake of anti-hypertensive medication in
participants with a physician’s diagnosis of hypertension (“awareness”). Participants with
hypertension were categorized into one of the following four subgroups: (1) aware (with physi-
cian’ diagnosis) and controlled treated to target levels of< 140/90 mmHg, (2) aware and
treated, but not reaching target blood pressure values of< 140/90 mmHg, i.e. uncontrolled
treated, (3) aware, but not treated, (4) unaware of hypertension. Thus, “awareness” of
Table 1. Studies included in the pooled sample (45–74 years), N = 5,939.
SHIPa CARLAb KORAc Total
Study periods: ●BL/●●FUP 1997–2001/2002–2006 2002–2006/2007–2010 1999–2001/2006–2008 1997–2006/2002–2010
Response at baseline (%) 69 64 67
Response at follow-up (%) 84 86 80
Mean observation time years(SD) 5.2 (0.6) 4.0 (0.3) 7.1 (0.2) 5.7 (1.3)
N (%) 2,219 (37.4) 1,356 (22.8) 2,364 (39.8) 5,939 (100.0)
Women % 50.4 47.3 50.7 49.8
Age BL mean (SD) 58.9 (8.5) 60.2 (7.9) 58.7 (8.6) 59.1 (8.4)
Age FUP mean (SD) 64.1 (8.5) 64.3 (7.9) 65.8 (8.6) 64.8 (8.5)
T2D* BL % 11.5 13.1 6.1 9.7
T2D* FUP % 17.3 18.5 12.2 15.6
Hypertension** BL % 65.7 71.5 49.2 60.4
Hypertension** FUP % 67.0 73.9 54.8 64.5
aSHIP (Survey S-0/S1): Study of Health in Pomerania—North-east Germany (West Pomerania)
bCARLA: Cardiovascular Disease, Living and Ageing in Halle—East Germany (Halle)
cKORA (Survey S4/F4): Cooperative Health Research in the Region of Augsburg—South Germany (Augsburg region)
●BL: Baseline
●●FUP: Follow-Up
*Self-reported diabetes or self-reported use of anti-diabetic medication
**Blood pressure 140/90 mmHg or using anti-hypertensive medication
doi:10.1371/journal.pone.0133493.t001
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hypertension applied to participants in categories 1, 2 and 3, “treatment” applied to those in
categories 1 and 2 and “control” to those in category 1.
The follow-up variable was delineated accordingly. However, the items in the questionnaires
were not absolutely identical in the studies: in the KORA study, the question aimed at any dis-
covery of hypertension irrespective of the kind of diagnosis (i.e. at a physician’s office, a phar-
macy or at home). Therefore, the frequency in KORA may be somewhat higher than in the
other two studies. The SHIP study asked for a physician’s diagnosis of hypertension during the
last 5 years, and the CARLA study inquired about a physician’s diagnosis during the time that
had passed since the baseline examination. We calculated the frequency of hypertension ‘ever’
for all follow-up examinations by including the information from the baseline examinations.
Pulse Pressure (PP). PP was calculated by the subtraction of diastolic blood pressure from
systolic blood pressure. A PP of greater than 50–65 mmHg is regarded to be unfavourable in
the literature (e.g. [10, 28]). We chose a cutting point of60 mmHg to define high PP.
Anti-hypertensive medication. All study participants were asked to bring original pack-
aging of their medications used during the last seven days to the examinations at baseline and
follow-up. The variable “anti-hypertensive medication” included prescription of medication
belonging to the ATC subgroups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking
agents), C08 (calcium channel blockers) and C09 (agents reacting on the renin-angiotensin
system), that were allowed for the treatment of chronic hypertension (e.g. as opposed to a one-
time treatment of an acute hypertensive crisis) according to the German Hypertension League
and/or the package inserts. Herbal (i.e. leaves of the stinging nettle, garlic, dandelion or others)
and homeopathic preparations were excluded.
Participants
For our current analyses, the pooled baseline data set consisted of 6,218 participants of German
nationality aged 45 to 74 years at baseline examination. Of those, 4,901 (78.8%) also attended
the follow-up examinations. Persons with missing data in one of the blood pressure variables
(measurement (N (baseline) = 11, N (follow-up) = 19), physician’s diagnosis (N (baseline) =
42, N (follow-up) = 30) and/or intake of anti-hypertensive medication (N (baseline) = 11, N
(follow-up) = 5) or missing information on T2D status (N (baseline) = 105, N (follow-up) =
139) were excluded. Thus, 4,683 participants with complete baseline and follow-up data on
blood pressure and T2D comprised the complete case population of our analyses.
To account for the 1,256 baseline participants with complete baseline data on blood pres-
sure and T2D who did not take part in the follow-up examinations, we calculated a weighted
data set, regarding study, sex, age and T2D status. Persons who were lost to follow-up tended
to be older, were more often male, suffered more often from T2D and had had a myocardial
infarction or stroke more often than their counterparts. The weighted dataset thus consisted of
5,939 entries based on the population of 4,683 participants with complete baseline and follow-
up information and 1,256 participants with complete baseline information on blood pressure
and T2D, respectively (S1 Fig).
Statistical analyses
To take the number of participants who were lost to follow-up into account and to relate asso-
ciations to the source population of 5,939 participants, most analyses (except for the linear
mixed model) were weighted using an inverse probability weighting approach stratified for sex,
age (10-year age groups), T2D status, and study [29]. Thus, all results refer to the weighted
dataset, if not stated otherwise. Robust variance estimations appropriate to the weighting
scheme were computed using the SAS procedures SURVEYMEANS and SURVEYFREQ.
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Descriptive methods with means, standard deviations, confidence intervals (95% CI) and
proportions were applied.
To assess the association of exposures with BP independent from potential confounding fac-
tors and over time, linear mixed models were computed for each variable of interest separately
and in a second step significant co-variables were included in a basic multivariable model to
examine adjusted effects. An unstructured correlation matrix was specified. SBP and DBP were
approximately normally distributed, after the assessment of histograms.
Additionally, to assess whether the results hold when outlying blood pressure values were
not considered, a sensitivity analysis was conducted excluding participants with baseline or fol-
low-up SPB below the baseline 5%-quantile or above the baseline 95%-quantile (i.e.108.5 or
177 mmHg).
We conducted additional analyses stratified by study to assess potential differences in find-
ings by studies. Since these analyses revealed comparable findings and supported our main
messages and conclusions, only the pooled results are presented.
A two-sided alpha level of 0.05 was chosen as criterion for statistical significance. All analy-
ses were carried out using SAS, version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Participants
The distributions of characteristics stratified for the three studies are presented in Table 1.
About 50% of the participants were women, the mean age at baseline was 59 years and the
mean age at follow-up was 65 years. At baseline, 10% had prevalent T2D –ranging from 6% in
KORA to 13% in CARLA. This estimate increased to 16% in the follow-up. The frequency of
hypertension across all participants defined by blood pressure measurements140/90 mmHg
or the intake of antihypertensive medication increased slightly from 60% at baseline to 64.5%
at follow-up. Median SBP at baseline was 137 mmHg, 25% of all participants had SBP> 151
mmHg, 5%> 175 mmHg and 1%> 194 mmHg. At follow up, the median SBP had decreased
to 132 mmHg– 25% of participants had SBP> 144 mmHg, 5%> 170 mmHg and 1%> 190
mmHg. Corresponding DBP measurements at baseline were 84 mmHg (median),> 91 mmHg
(25%),> 103 mmHg (5%) and> 113 mmHg (1%) and 79 mmHg (median),> 86 mmHg
(25%),> 98 mmHg (5%) and> 108 mmHg (1%) at follow-up.
Degrees of awareness, treatment and control of hypertension, stratified
by T2D status
Participants who reported incident T2D at the follow-up examinations were still non-diabetic
(though possibly pre-diabetic or undiagnosed) at baseline, but were regarded as persons with
future T2D and thus termed ‘incident T2D group’ in baseline and follow-up. Thus, 84.4% of the
study participants were not affected by T2D, 5.8% had incident and 9.7% had prevalent T2D.
Participants without T2D were younger and more often female than participants with inci-
dent or prevalent T2D. As presented in Table 2, the frequency of hypertension (known or
unknown) was much higher in participants with T2D than in those without T2D (85.2% vs.
56.5%) and increased by about 5% in all T2D groups from baseline to follow-up. During the
same time, the degrees of awareness, treatment and control increased substantially, especially
in persons with prevalent or incident T2D. The degrees of treatment reached more than 90% in
people with T2D. However, even though they approximately doubled, the degrees of control
remained insufficiently low at around 50%, somewhat higher in those without T2D and with
incident T2D than in those with prevalent T2D.
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Irrespective of T2D status and examination time, the degrees of awareness, treatment and
control in those with hypertension increased with increasing age. Control in those treated for
hypertension was similar in all three age groups (data not shown).
Trends in blood pressure parameters and hypertension control between
baseline and follow-up
S1 Table shows mean SBP, DBP, and PP measurements stratified for T2D status and baseline /
follow-up as well as calculated differences between the baseline and follow-up pairs respec-
tively. The mean SBP increased from non-T2D (137.09 mmHg) to prevalent T2D (148.52
mmHg) and decreased consistently in all T2D groups from baseline to follow-up, antidromic
to the usual increase of SBP with increasing age. The greatest reduction was found in incident
Table 2. Degrees of awareness, treatment, and control at baseline and follow-up, stratified by T2D status and sex.
Non-T2D Non-T2D Future incident T2D Incident T2D Prevalent T2D Prevalent T2D
●BL ●●FUP BL FUP BL FUP
Frequency of known or unknown hypertension
Total 56.5 (55.2; 57.9) 60.3 (59.0; 61.7) 75.7 (71.2; 80.2) 81.6 (77.5; 85.7) 85.2 (82.3; 88.1) 90.3 (87.9; 92.7)
Women 49.5 (47.5; 51.4) 55.8 (53.9; 57.7) 73.6 (66.1; 81.1) 78.6 (71.6; 85.6) 88.6 (84.7; 92.4) 92.0 (88.8; 95.3)
Men 63.9 (62.0; 65.8) 65.1 (63.2; 66.9) 77.0 (71.3; 82.6) 83.5 (78.5; 88.4) 82.3 (78.1; 86.6) 88.9 (85.3; 92.3)
Awareness of hypertension in those with hypertension
Total 66.6 (64.9; 68.4) 85.1 (83.8; 86.3) 79.8 (75.0; 84.7) 96.0 (93.7; 98.3) 83.3 (80.0; 86.6) 95.5 (93.7; 97.3)
Women 73.9 (71.5; 76.4) 87.9 (86.2; 89.6) 85.6 (78.7; 92.6) 98.9 (96.8; 100.0) 91.3 (87.7; 94.9) 97.8 (96.0; 99.6)
Men 60.7 (58.3; 63.2) 82.5 (80.7; 84.4) 76.4 (69.9; 82.9) 94.3 (90.9; 97.7) 76.0 (70.8; 81.2) 93.4 (90.5; 96.3)
Treatment for hypertension in those with hypertension
Total 48.1 (46.3; 50.0) 73.2 (71.6; 74.8) 65.5 (59.7; 71.2) 91.6 (88.3; 94.8) 75.0 (71.2; 78.8) 91.0 (88.6; 93.5)
Women 55.9 (53.2; 58.7) 76.9 (74.7; 79.1) 73.7 (65.0; 82.5) 94.1 (89.6; 98.6) 84.4 (79.8; 89.0) 96.1 (93.7; 98.6)
Men 41.8 (39.4; 44.3) 69.9 (67.6; 72.1) 60.5 (53.1; 68.0) 90.0 (85.6; 94.4) 66.3 (60.6; 72.1) 86.5 (82.4; 90.5)
Treatment for hypertension in those aware of hypertension
Total 72.2 (70.2; 74.2) 86.0 (84.7; 87.4) 82.0 (76.8; 87.2) 95.4 (92.9; 97.9) 90.0 (87.1; 92.9) 95.3 (93.5; 97.2)
Women 75.6 (72.9; 78.4) 87.5 (85.7; 89.3) 86.1 (78.7; 93.5) 95.2 (91.1; 99.3) 92.4 (88.9; 96.0) 98.3 (96.7; 99.9)
Men 68.9 (65.9; 71.8) 84.7 (82.7; 86.6) 79.2 (72.1; 86.3) 95.5 (92.3; 98.6) 87.3 (82.6; 92.0) 92.6 (89.4; 95.8)
Controlled hypertension in those with hypertension
Total 17.8 (16.4; 19.2) 43.6 (41.8; 45.3) 24.6 (19.4; 29.8) 53.5 (47.7; 59.3) 23.7 (20.0; 27.5) 44.4 (40.2; 48.7)
Women 24.6 (22.2; 26.9) 49.9 (47.3; 52.5) 32.7 (23.4; 42.0) 56.1 (46.6; 65.6) 37.3 (31.1; 43.4) 50.1 (43.9; 56.4)
Men 12.4 (10.8; 14.0) 37.9 (35.5; 40.3) 19.8 (13.7; 25.9) 52.0 (44.6; 59.3) 11.2 (7.3; 15.1) 39.4 (33.6; 45.1)
Controlled hypertension in those aware of hypertension
Total 26.7 (24.7; 28.7) 51.2 (49.3; 53.1) 30.8 (24.5; 37.0) 55.7 (49.8; 61.6) 28.5 (24.1; 32.8) 46.5 (42.2; 50.9)
Women 33.2 (30.2; 36.2) 56.8 (54.0; 59.5) 38.1 (27.7; 48.6) 56.7 (47.2; 66.3) 40.8 (34.3; 47.4) 51.3 (44.9; 57.6)
Men 20.4 (17.8; 23.0) 45.9 (43.2; 48.6) 25.9 (18.2; 33.5) 55.1 (47.6; 62.6) 14.8 (9.8; 19.7) 42.1 (36.1; 48.2)
Controlled hypertension in those treated for hypertension
Total 37.0 (34.5; 39.6) 59.5 (57.5; 61.6) 37.5 (30.3; 44.8) 58.4 (52.4; 64.4) 31.6 (26.9; 36.4) 48.8 (44.3; 53.3)
Women 43.9 (40.2; 47.6) 64.9 (62.1; 67.7) 44.3 (32.8; 55.8) 59.6 (49.9; 69.3) 44.2 (37.3; 51.1) 52.1 (45.8; 58.5)
Men 29.6 (26.1; 33.1) 54.2 (51.3; 57.2) 32.6 (23.4; 41.9) 57.7 (50.1; 65.4) 16.9 (11.3; 22.5) 45.5 (39.2; 51.8)
Numbers are weighted and given as % with 95% CI in brackets.
●BL: Baseline
●●FUP: Follow-Up
Hypertension was defined as blood pressure 140/90 mmHg and/or intake of anti-hypertensive medication.
doi:10.1371/journal.pone.0133493.t002
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T2D with -8.55 mmHg. The DBP was similar in all groups and decreased from 84.38 mmHg to
77.28 mmHg in prevalent T2D. The PP was markedly higher in persons with T2D than in per-
sons without T2D (64.14 mmHg in prevalent T2D compared to 52.87 mmHg in non-T2D)
and did not change much between the two examinations.
Trends of blood pressure treatment and control are illustrated in S2 Fig and Fig 1: In the
baseline examinations, a much greater percentage of participants without T2D was free of
hypertension than of those with T2D (42% vs. 15%). Compared to baseline, the percentage of
participants with high blood pressure increased slightly in participants without T2D, the per-
centage with controlled treated hypertension more than doubled (from 10 to 26%), while the
number of persons with insufficiently treated hypertension approximately stayed the same
(18%). Both untreated known and untreated unknown hypertension became less frequent.
In participants with prevalent T2D, the percentage without hypertension decreased as well,
while the number of controlled treated persons increased greatly from 20 to 40%. Insufficiently
treated hypertension remained similar at about 43%. As in people without T2D, the frequencies
of untreated and unknown hypertension became rare (each about 4%).
Finally, participants with incident T2D as reported in the follow-up examinations stood
between people without and people with prevalent T2D: in follow-up 18% were not affected
with hypertension, 44% were controlled treated, 31% were insufficiently treated, 4% had
untreated and 3% unknown hypertension. Thus, the number of people affected with hyperten-
sion has increased in all subgroups with time. The frequencies of controlled treated hyperten-
sion increased markedly in all T2D groups, the frequencies of insufficiently treated
hypertension remained stable and the percentages of untreated and unknown cases decreased
consistently.
Fig 1 presents analogous percentages in people with incident or prevalent T2D stratified by
sex. Hence, the estimate of men with controlled hypertension has caught up on the percentage
of women in follow-up. Persons with incident T2D were still not as often affected by hyperten-
sion as people with prevalent T2D. Treatment and control were similar in incident and prevalent
T2D and the number of persons with unknown hypertension was small, especially in women.
Hypertension and concomitant high pulse pressure by T2D status and
age
With increasing age and T2D status, the percentages of participants with an unfavorable com-
bination of both uncontrolled blood pressure (140/90 mmHg) and high PP (60 mmHg) in
follow-up increased consistently. In participants without T2D, aged 45 to 54 years, 9% had
both conditions, compared to 17% of participants with prevalent T2D in the same age group.
In the age group of 75 to 83 years this number increased to 31% in people without and 55% in
people with prevalent T2D. Incident T2D stood in between in most age groups (S3 Fig).
Means and 95% CIs of SBP in baseline and follow-up, stratified by sex and T2D status are
depicted in Table 3. SBP was generally higher in men than in women. The respective means in
each T2D subgroup decreased considerably more in men than in women from baseline to fol-
low-up (e.g. -9.2 mmHg vs. –7.5 mmHg in people with incident T2D) however, mean readings
in follow-up were still clearly higher in men then in women.
Adjusted analyses including basic personal attributes associated with
SBP and change in SBP: Linear mixed models
Adjusted linear mixed models confirmed this association and generated further insights
(Table 4): Including observation time, sex, age at baseline, study, T2D at follow-up and interac-
tion terms of each variable with follow-up time, we found that SBP was significantly lower in
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KORA than in SHIP and CARLA and participants of KORA and CARLA had greater reduc-
tions of SBP from baseline to follow-up. Compared to the youngest age group (45–54 years)
SBP was 3 mmHg higher in persons aged 55–64 and 9 mmHg higher in persons aged 65–74.
At follow-up, however, SBP had decreased more in the oldest than the youngest and middle-
Fig 1. Sex-stratified frequencies of controlled treated, uncontrolled, known but untreated and unknown hypertension in participants with
prevalent and (future) incident T2D in the baseline and follow-up examinations.Hypertension was defined as blood pressure140/90 mmHg.Numbers
are weighted and given as %.
doi:10.1371/journal.pone.0133493.g001
Table 3. Descriptive changes in systolic blood pressure stratified by sex and T2D status.
Men (50.2%) Total Non-T2D Incident T2D Prevalent T2D
% 100.0 82.4 7.2 10.4
Mean SBP,●BL 142.84 141.33 146.30 152.42
95% CI (142.03; 143.65) (140.48; 142.19) (143.25; 149.34) (149.42; 155.41)
Mean SBP, ●●FUP 136.40 135.49 137.10 143.04
95% CI (135.58; 137.21) (134.63; 136.36) (133.63; 140.56) (140.09; 145.98)
Difference (FUP-BL) -6.45 -5.84 -9.20 -9.38
95% CI (-7.29; -5.61) (-6.72; -4.95) (-12.80; -5.61) (-12.50; -6.26)
Women (49.8%)
% 100.0 86.5 4.5 9.0
Mean SBP, BL 134.31 133.01 139.81 143.99
95% CI (133.48; 135.14) (132.16; 133.87) (135.79; 143.85) (140.86; 147.12)
Mean SBP, FUP 129.97 128.82 132.30 139.76
95% CI (129.14; 130.79) (127.97; 129.68) (128.55; 136.05) (136.40; 143.13)
Difference (FUP-BL) -4.34 -4.19 -7.52 -4.23
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aged groups (-3 mmHg). People with prevalent T2D had highest SBP readings (+8 mmHg),
followed by people with incident T2D (+5 mmHg) as compared to those without T2D. These
values decreased most in incident T2D (-3 mmHg).
Using effect estimators of the model we calculated two exemplary profiles: A woman, aged
45–54 years, with an observation time of 5.6 years, who participated in KORA and did not
have T2D would have a SPB of 118 mmHg at follow-up. In contrast, a man in the oldest age
group, with an observation time of 5.6 years, who participated in SHIP and had prevalent T2D
would have a SBP of 149 mmHg at follow-up.
Exemplary FUP-SBP calculations with mean observation time of 5.6
years
Young KORA woman without T2D. 133.82 (intercept) – 3.86 (FUP) +7.34 (mean obser-
vation time) - 7.94 (woman) + 1.80 (woman change) – 10.38 (KORA) – 2.77 (KORA change)
+ 0 (age 45–54) + 0 (no T2D) = 118.01 mmHg
Elderly SHIP man with prevalent T2D. 133.82 (intercept) – 3.86 (FUP) + 7.34 (mean
observation time) + 0 (man) + 0 (SHIP) + 8.94 (age 65–74) – 3.22 (65–74 change) + 7.81 (prev-
alent T2D) – 1.83 (prevalent T2D change) = 149.00 mmHg
Table 4. Linear mixedmodel including observation time, sex, BL-age, study, FUP-T2D and interaction
terms with time as covariates and systolic BP as outcome (N = 4683, complete case dataset).
ß p-value
Intercept 133.82 < .0001
Time ●BL (ref.) 0
Time ●●FUP -3.86 < .0001
Observation time/yearMean time 5.6 years 1.317.34 0.0307
Sex Women -7.94 < .0001
Sex Men (ref.) 0
Women*FUP 1.80 0.0017
Study CARLA 1.71 0.0871
Study KORA -10.38 < .0001
Study SHIP 0
CARLA*FUP -1.98 0.0073
KORA*FUP -2.77 < .0001
BL-Age 45–54 (ref.) 0
BL-Age 55–64 3.42 < .0001
BL-Age 65–74 8.94 < .0001
55–64*FUP 1.29 0.0536
65–74*FUP -3.22 < .0001
T2D No (ref.) 0
T2D Incident 4.91 < .0001
T2D Prevalent 7.81 < .0001
Incident T2D*FUP -3.12 0.0115
Prevalent T2D*FUP -1.83 0.0797




I-M. Rueckert et al.: Improvement in Blood Pressure Control
PLOS ONE | DOI:10.1371/journal.pone.0133493 July 29, 2015 10 / 16
Sensitivity analyses to regarding outlying values
In a sensitivity analysis, we excluded participants with baseline or follow-up SPB below the
baseline 5%-quantile or above the baseline 95%-quantile (i.e.108.5 or177 mmHg, 17.1%)
to assess possible effects of outlying blood pressure values. Since the results of descriptive anal-
yses and the adjusted linear mixed model remained similar (data not shown), we assume that
regression-to-the-mean played a minor role in our study.
Numbers and percentages of anti-hypertensive drugs
In the subgroup of participants with a physician’s diagnosis of hypertension and anti-hyperten-
sive treatment both at baseline and follow-up (Table 5), one to eight different preparations and
one to eight active agents were used. Combinations of different active agents in one preparation
are very common in Germany (taking only one pill instead of two or more is considered to
improve patient adherence).
The mean number of preparations and active components used increased from baseline to
follow-up in all T2D groups (except for the ATC group “other anti-hypertensives”). Partici-
pants with prevalent T2D used more drugs than participants without T2D or with incident
T2D. At follow-up most people still used the same drug group(s) they had used at baseline, but
a considerable percentage changed (data not shown).
Discussion
Key results
Using data of the German DIAB-CORE Consortium, we found that blood pressure management
has developed positively during past years. At baseline and follow-up hypertension prevalence,
awareness and treatment were considerably higher in participants with T2D than in those
Table 5. Numbers of preparations and active agents and percentages of anti-hypertensive medications groups.
Non-T2D Non-T2D Future incident
T2D
Incident T2D Prevalent T2D Prevalent T2D
●BL ●●FUP BL FUP BL FUP
number of preparations* 1.6 (1.5; 1.6) 2.0 (1.9; 2.0) 1.7 (1.6; 1.9) 2.1 (2.0; 2.3) 2.0 (1.8; 2.1) 2.4 (2.2; 2.5)
number of diff. active
components
1.9 (1.8; 2.0) 2.4 (2.3; 2.5) 2.1 (1.9; 2.3) 2.7 (2.5; 2.9) 2.4 (2.2; 2.5) 2.9 (2.8; 3.1)


















































% other anti-hypertensives 5.7 (4.4; 7.0) 5.3 (4.1; 6.5) 9.7 (5.2; 14.3) 6.8 (3.0; 10.6) 12.8 (9.4; 16.3) 12.7 (9.3; 16.2)
Numbers are weighted and given with 95% CI.
●BL: Baseline
●●FUP: Follow-Up
*including combinations of different active agents
**percentage of study participants who used at least one active component from this group
doi:10.1371/journal.pone.0133493.t005
I-M. Rueckert et al.: Improvement in Blood Pressure Control
PLOS ONE | DOI:10.1371/journal.pone.0133493 July 29, 2015 11 / 16
without T2D.While awareness and treatment improved clearly between baseline and follow-up,
especially in those with T2D (reaching more than 90%), hypertension control was achieved only
in about half the number of people irrespective of T2D status. In contrast to the known elevation
of SBP with advancing age, SBP decreased in all subgroups by 5.0 to 8.6 mmHg. However, the
percentages of people with uncontrolled high blood pressure were still considerable, especially in
the older age groups. Persons with incident or prevalent T2D were still often insufficiently treated.
For example, more than 35% of those aged 55 to 64 years in follow-up with prevalent T2D had
uncontrolled blood pressure140/90 mmHg and concomitant PP60 mmHg. Fortunately, the
percentages of participants with unknown or known but untreated hypertension have become
very small. The linear mixed model figured out that blood pressure in men improved more than
in women at follow-up, however, men still had higher mean readings than women. The KORA
study had more favourable results than the other studies. SBP decreased more in the oldest than
in the youngest and middle-aged groups. People with prevalent T2D had highest SBP, followed
by people with incident T2D and those without T2D. At follow-up, SBP had decreased most in
those with incident T2D. These results indicate more intensive treatment in hitherto more prob-
lematic groups, namely in men, older people and those with newly diagnosed diabetes.
Generalization
Some German and various international studies have analysed trends in hypertension control
in people with and/or without T2D which were in line with our results. For Germany, a
recently published study by Neuhauser et.al [30] used data of 7,108 adult participants of the
German Health Interview and Examination Survey (GNHIES98, 1998) as baseline and 7,095
participants of the German Health Interview and Examination Survey for Adults (DEGS1,
2008–2011) as follow-up study. The mean systolic blood pressure in GNHIES98 was lower
than in our study (e.g. women aged 45–64 years: 131.3 vs. 131.6 mmHg, men aged 45–64 years:
133.2 vs. 140.9 mmHg). An improvement of awareness, treatment and control was reported
between GNHIES98 and DEGS1. Blood pressure control increased at an order of magnitude,
which is well comparable to DIAB-CARE: among GNHIES98/DEGS1 participants hyperten-
sion control increased from 23% to 51% and among all DIAB-CARE participants regardless of
T2D status from 19% to 44%. Degrees of treatment and awareness were also similar. In our
study 76% of all participants who were aware of having hypertension used at least one antihy-
pertensive drug at baseline and 88% at follow-up compared to 79% and 88% in GNHIES98/
DEGS1, which is also very well comparable. Moreover, GNHIES98/DEGS1 found more benefi-
cial readings in women than in men as we did in our study.
Ott et al. (2009) [31] conducted a prospective 4-year follow-up study in 2,914 patients with
T2D aged 35–80 years in daily practice and found very little improvement from 2002 to 2007.
Mean blood pressure decreased from 139.3/80.0 mmHg at BL baseline to 137.3/79.9 mmHg at
follow-up and anti-hypertensive medication was prescribed more often. Labeit et al. (2012)
[32] compared 55,518 primary care patients with and without T2D that were recruited in 2003
in the course of the DETECT study, with the HYDRA study which was conducted in 2001. The
estimates of treated and controlled hypertension remained low at about 56% and 20% with
some minor improvement. Using three surveys of the KORA study conducted between 1999
and 2008, Schunk et al. found clearer enhancements in blood pressure control in participants
with T2D: the proportions of people who achieved the goal blood pressure of< 140/90 mmHg
were 43.6%, 55.2%, and 70.5% across the three studies sorted by examination dates [33].
Furthermore, results of the KORA study from 2008 indicated that participants of disease man-
agement programs (DMPs) for people with T2D that were launched in 2002, reached the same
treatment goal significantly more often (79.8% vs. 63.6%, p-value: 0.037) than controls [34].
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Finally, international findings are consistent: longitudinal studies on hypertension trends
from the Netherlands (1998–2004) [35], Spain (2003–2009) [36], the US (1988–2008 and
2001–2010) [37, 38], and China (1982–2010) [39] consentaneously concluded that hyperten-
sion management has improved, but remains insufficient and in need for further monitoring
and enhancement.
Strengths and Limitations
Our dataset included three population-based studies with well comparable questionnaires and
measurements. Nevertheless, we cannot exclude systematic divergences due to slightly different
designs, protocols or measuring devices. This is also true for the comparability of baseline and
follow-up examinations as conditions may change. However, the improvement of mean blood
pressure control was consistent in all studies though and thus appears very plausible.
Using longitudinal data, we were able to track changes between baseline and follow-up read-
ings from each individual participant and draw conclusions to a general improvement of blood
pressure control over time. However, we cannot rule out that a potential bias due to loss to fol-
low-up may have influenced our findings. To compensate for this missing follow-up informa-
tion, we applied an inverse probability weighting approach which is aimed to reduce a
potential bias [29].
The observation times were different across and within studies. This was accounted for in
the adjusted models, but not considered in the descriptive results.
By applying inverse probability weighting, we intended to improve the internal quality of
our study. However, we do not claim representativeness of our data regarding the population
of Germany.
As in our previous publications on blood pressure [23, 24], we could not identify partici-
pants with “white coat hypertension”, who may be represented by a part of those with
unknown, uncontrolled or insufficiently controlled hypertension. This form of hypertension
occurs in the special setting of a physician’s office and might also have affected participants in
the study centres due to the unfamiliar situation. In an untreated Finnish population, the prev-
alence of white coat hypertension was about 15% and risk factors included lower BMI and
non-smoking status [40]. Taking three measurements and the mean of the second and third
reading for our analyses might have diminished this phenomenon.
Finally, the participants received letters with their diagnostic findings subsequent to the
examinations at the study centres and were asked to consult a physician if they had elevated
blood pressure measurements. This information might have induced some improvement in
hypertension control, but we do not assume that the bigger part of our results is due to this
one-time intervention effect.
Conclusion and prospect
Our pooled analyses including three regional population-based studies intended to contribute
information on the development of health care regarding hypertension in people with and
without T2D in Germany. In accordance with other German and international investigations,
we found that the degrees of awareness, treatment and control increased considerably, but nev-
ertheless remained insufficient. Even though more than 90% of people with T2D and hyperten-
sion are aware and treated for their high blood pressure, target values are only reached by
about 50%. This number is even lower than in people without T2D (with about 60%), indicat-
ing that treatment regimens, agents, combinations etc. are not yet optimally adjusted, especially
in diabetes care. Although a great number of different anti-hypertensive medications has been
approved and is currently in use, successful treatment of hypertension is not a trivial subject. In
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the light of its outstanding importance for health in developed and developing countries,




S2 Fig. Frequencies of controlled treated, uncontrolled, known but untreated and unknown
hypertension in participants without, with prevalent and with incident T2D in the baseline
and follow-up examinations.Hypertension was defined as blood pressure140/90 mmHg,
N = 5,939, weighted dataset.
(TIF)
S3 Fig. Percentages of participants with uncontrolled blood pressure140/90 mmHg and
concomitant pulse pressure values60 mmHg, stratified by T2D and age groups in the fol-
low-up examinations.
(TIF)
S1 Table. Blood pressure parameters at baseline and follow-up, stratified by T2D status.
Numbers are weighted and given as means with 95% CI in brackets, SBP: Systolic blood pres-
sure. DBP: Diastolic blood pressure. PP: Pulse pressure. ●BL: Baseline. ●●FUP: Follow-Up.
(DOC)
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